Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveYUTO Packaging Q3 Net Profit Falls 9.1% Year Over Year

Live News EQUITY FLASH M impact Oct 19, 2026, 10:08 AM UTC

YUTO Packaging Q3 Net Profit Falls 9.1% Year Over Year

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

002831

Related stories

IRON Trading to Resume at 7:20 a.m. IRON is scheduled to resume trading at 7:20 a.m. L impact | EQUITY | Oct 19, 2026, 11:09 AM UTC Teamshares Refinances $150M Facility, Expects About $8M in Annual Interest Savings Teamshares repaid a $150 million facility with a new $130 million term loan priced at SOFR+9.5% and cash, and began repaying $17 million of mezzanine debt. It expects about $5 mill M impact | EQUITY | Oct 19, 2026, 11:08 AM UTC Erdene Reports Q3 Gold Sales of 11,853 Ounces, Repays $20M Debt Erdene reported Q3 sales of 11,853 ounces of gold and 3,046 ounces of silver, generating $51 million in gross revenue. EM repaid $20 million of debt, reducing the balance to $93 mi M impact | EQUITY | Oct 19, 2026, 11:08 AM UTC PyroGenesis Receives $2.3 Million Payment Under Existing Drosrite Contract PyroGenesis said it received a $2.3 million payment under an existing contract with a Saudi client. Seven Drosrite systems have been deployed, and the original contract has been fu L impact | EQUITY | Oct 19, 2026, 11:08 AM UTC Rubicon Organics Closes $3 Million Strategic Private Placement Rubicon Organics says it closed a non-brokered private placement to expand Pacifica cultivation capacity. M impact | EQUITY | Oct 19, 2026, 11:08 AM UTC Summit Therapeutics Opens Phase II Study of Ivonescimab Regimens The global Phase II study will evaluate ivonescimab-based regimens in advanced clear cell renal cell carcinoma. L impact | EQUITY | Oct 19, 2026, 11:05 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.